Moderna FDA Review Moves Forward for mRNA Vaccine
Moderna FDA review advances after FDA accepted an amended BLA and set a PDUFA goal date, clarifying regulatory timing and reducing uncertainty for traders.
KEY TAKEAWAYS
- FDA accepted Moderna's amended BLA for mRNA-1010 and assigned a PDUFA goal date of Aug. 5, 2026.
- Acceptance followed a Refusal-to-File over comparator choice that raised no safety or efficacy concerns.
- Moderna proposed an age-based pathway: full approval for 50-64 and accelerated approval for adults 65+.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Moderna, Inc. said in a February 18, 2026 press release that the FDA’s Center for Biologics Evaluation and Research accepted its amended biologics license application (BLA) for mRNA-1010 and set a Prescription Drug User Fee Act (PDUFA) goal date of August 5, 2026. The review could clear the vaccine for U.S. adults 50 and older for the 2026–27 flu season.
FDA Acceptance and Regulatory Timeline
The FDA had issued a Refusal-to-File letter around February 10, 2026, citing concerns about the choice of comparator in Moderna’s pivotal trials. The agency raised no safety or efficacy issues. Moderna held a Type A meeting with the FDA and amended its submission to address the comparator concern. Chief Executive Stéphane Bancel said, "We appreciate the FDA's engagement in a constructive Type A meeting and its agreement to advance our application for review."
Moderna proposed an age-based approval pathway: full approval for adults 50 to 64 and accelerated approval for adults 65 and older, with the latter contingent on a post-marketing study. The PDUFA goal date sets the regulatory timeline for potential authorization decisions.
Clinical Data and Market Scope
Moderna’s Phase 3 program includes P303, an immunogenicity and safety study in adults 65 and older using a high-dose comparator, and P304, an efficacy trial in adults 50 and older using a standard-dose comparator. Both trials met their primary endpoints with statistical superiority. The inclusion of a high-dose comparator in the older-adult study addressed the FDA’s earlier concern and was central to the amended submission.
Outside the U.S., regulators in Europe, Canada, and Australia have accepted Moderna’s applications for review. The company plans additional filings throughout 2026 as it seeks authorizations in multiple markets ahead of the next flu season.
The announcement did not include new financial guidance or related SEC filings. Moderna’s risk disclosures remain as filed in its Form 10-K for the year ended December 31, 2024.
